Oncology News | pharmaphorum

News

Sanofi backs precision oncology firm Nucleai in $33m fundrai...

Israeli startup Nucleai has raised $33 million in a second-round financing that will be used to further its work on using artificial inte

News

Bayer backs KRAS TCR player Affini-T in $175m financing

Bayer's venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for cancer cells with mutations like KRAs and p53

News

Keytruda encroaches on Jemperli's endometrial cancer territo...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with cert

News

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co.

News

Merck fights back against Roche in adjuvant lung cancer ther...

Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returnin

News

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development.

Sanofi backs precision oncology firm Nucleai in $33m fundrai...

Bayer backs KRAS TCR player Affini-T in $175m financing

Keytruda encroaches on Jemperli's endometrial cancer territo...

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Merck fights back against Roche in adjuvant lung cancer ther...

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Vanda ends 40-year hiatus for new motion sickness drugs

How to meet your physicians where they are online

News

Editor's Picks